[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353843-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353843-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","radiotherapy-improves-outcomes-in-patients-with-nsclc-receiving-nivolumab","Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab","","Background: Despite advances in systemic therapies, non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality. While immune checkpoint inhibitors (ICIs) improve outcomes, durable responses occur only in a subset, and radiotherapy (RT) may enhance antitumor immunity via tumor microenvironment modulation. Methods: This retrospective study evaluated advanced NSCLC patients treated with nivolumab after first-line platinum-based chemotherapy between 2015 and 2025, assessing RT given before or during nivolumab. Results: RT use correlated with longer PFS and OS. Conclusions: RT combined with nivolumab improved survival outcomes, though selection bias requires cautious interpretation and prospective validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/radiotherapy-improves-outcomes-in-patients-with-nsclc-receiving-nivolumab/353843/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/radiotherapy-improves-outcomes-in-patients-with-nsclc-receiving-nivolumab/353843.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of evaluating radiotherapy in NSCLC patients receiving nivolumab?","Question",{"text":63,"@type":64},"To assess the association between radiotherapy and survival outcomes in advanced NSCLC treated with nivolumab.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were progression-free survival (PFS) and overall survival (OS) analyzed?",{"text":68,"@type":64},"PFS and OS were evaluated using Kaplan–Meier estimates and Cox regression models.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about patients who received radiotherapy?",{"text":72,"@type":64},"Patients receiving radiotherapy had significantly longer PFS and OS than those who did not, including notable outcomes in the oligoprogression RT subgroup.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353843,1790185291,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Saray et al. BMC Cancer (2026) 26:339 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15805-w](https://doi.org/10.1186/s12885-026-15805-w)  \nRESEARCH Open Access  \nRadiotherapy improves outcomes in patients with NSCLC receiving nivolumab  \nSeray Saray1*, Berke Engin2, Ahmet Kadıoğlu1, Mustafa Akın3, Hüseyin Kanmaz1 andYakup İriağaç1  \nAbstract  \nBackground Despite significant advances in systemic therapies, non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs) have improved outcomes in advanced disease, durable responses occur in only a subset of patients. Radiotherapy (RT) may enhance antitumor immunity by modulating the tumor microenvironment. This study aimed to evaluate the association between RT and survival outcomes in patients with advanced NSCLC treated with nivolumab.  \nMethods This retrospective study included patients with advanced NSCLC who progressed after first-line platinumbased chemotherapy and received nivolumab as second-line therapy between January 2015 and January 2025. Patients who received RT before or during nivolumab, including RT for oligoprogression, were evaluated. Progressionfree survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression models. Results A total of 191 patients were included. The median age was 64 years (range, 37–83), and adenocarcinoma and squamous cell carcinoma accounted for 47 . 6% and 44% of cases, respectively. Median PFS and OS were 6.9 and 14.1 months, respectively. Patients who received RT had significantly longer PFS (11 . 9 vs. 3.6 months; p \u003C 0. 001) and OS (31 .8 vs. 8.3 months; p \u003C 0. 001) compared with those who did not. Median PFS was not reached in patients receiving RT for oligoprogression, with 57% remaining progression-free at 6 months. Multivariate analysis identified ECOG performance status, RT history, and adrenal metastases as independent predictors of PFS, while ECOG performance status, prior surgery, RT history, and brain and adrenal metastases were independent predictors of OS.  \nConclusions RT administered before or during nivolumab was associated with improved survival outcomes in advanced NSCLC. However, given the retrospective design and potential selection bias, these findings should be interpreted cautiously. Prospective studies are needed to clarify the optimal integration and timing of RT with ICIs. Keywords NSCLC, nivolumab, radiotherapy  \n*Correspondence:  \nSeray Saray  \n[drseraysaray@gmail.com](drseraysaray@gmail.com)  \n1Medical Oncology Department, Internal Medicine, Balikesir Ataturk City Hospital, Balikesir, Turkey  \n2Internal Medicine Department, Balikesir Ataturk City Hospital, Balikesir, Turkey  \n3Radiation Oncology Department, Balikesir Ataturk City Hospital, Balikesir, Turkey  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nSara","cbCaiojcCpSoNxCx","https://ap.wps.com/l/cbCaiojcCpSoNxCx","pdf",1714053,"English","# Abstract\n# Introduction\n## Immune checkpoint inhibition and nivolumab in NSCLC\n## Rationale for combining RT with ICIs","[{\"question\":\"What was the purpose of evaluating radiotherapy in NSCLC patients receiving nivolumab?\",\"answer\":\"To assess the association between radiotherapy and survival outcomes in advanced NSCLC treated with nivolumab.\"},{\"question\":\"How were progression-free survival (PFS) and overall survival (OS) analyzed?\",\"answer\":\"PFS and OS were evaluated using Kaplan–Meier estimates and Cox regression models.\"},{\"question\":\"What did the study find about patients who received radiotherapy?\",\"answer\":\"Patients receiving radiotherapy had significantly longer PFS and OS than those who did not, including notable outcomes in the oligoprogression RT subgroup.\"}]","Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab | PDF",1790107511,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c366be1a4c7b791d1620a2be565b3a4.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02af2362cb00d709ca2e153ecb99f845.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0eb08e4851f94af023f55243052f9d3.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7334fad417e5d45db9693e0e9218a25.webp",980,1306]